Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4034.86% is 43% below its 5-year average of -2812.60%, near the high end of its 5-year range (-13078.14%–-1036.85%).
49.70% above its 12-month average of -8022.10%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -9893.71%.
EBITDA MARGIN
-4034.86%
EBITDA MARGIN AVG TTM
-8022.10%
EBITDA MARGIN AVG 3Y
-4067.61%
EBITDA MARGIN AVG 5Y
-2812.60%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+49.70%
CURRENT VS 3Y AVG
+0.81%
CURRENT VS 5Y AVG
-43.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Absci Corporation
Market Cap
$1.99B
EBITDA Margin
-4034.86%
TTM Avg
-8022.10%
3Y Avg
-4067.61%
5Y Avg
-2812.60%
Market Cap
$1.97B
EBITDA Margin
-13.52%
TTM Avg
-19.53%
3Y Avg
-24.36%
5Y Avg
-23.78%
Market Cap
$2.09B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
Market Cap
$1.89B
EBITDA Margin
3.75%
TTM Avg
2.81%
3Y Avg
-0.66%
5Y Avg
-2.07%
Market Cap
$2.03B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.04B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$1.88B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Absci Corporation (ABSI) | $1.99B | -4034.86% | -8022.10% | -4067.61% | -2812.60% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.97B | -13.52% | -19.53% | -24.36% | -23.78% |
| Azenta, Inc. (AZTA)vs › | $2.01B | 8.41% | 9.50% | 6.21% | 7.73% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 0.15% | 1.29% | -6.34% | -9.86% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.09B | 1.74% | -0.52% | 3.36% | 2.51% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.03B | 40.34% | 23.31% | -20.04% | -112.62% |
| Immunome, Inc. (IMNM)vs › | $2.04B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.88B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.06B | 7.12% | 6.21% | -1.19% | -11.55% |
Gross Margin
-319.4%
EBITDA Margin
-4034.9%
Operating Margin
-4454.2%
Net Margin
-7756.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -9893.71% |
| 2026-03-31 | -13078.14% |
| 2025-12-31 | -5125.23% |
| 2025-09-30 | -7225.40% |
| 2025-06-30 | -4788.03% |
| 2025-03-31 | -2091.35% |
| 2024-12-31 | -3990.98% |
| 2024-09-30 | -1501.47% |
| 2024-06-30 | -1837.56% |
| 2024-03-31 | -2236.30% |
| 2023-12-31 | -6288.46% |
| 2023-09-30 | -2659.95% |
| 2023-06-30 | -1172.85% |
| 2023-03-31 | -1653.35% |
| 2022-12-31 | -1124.41% |
| 2022-09-30 | -1036.85% |
| 2022-06-30 | -2569.46% |
| 2022-03-31 | -3162.03% |
| 2021-12-31 | -1618.25% |
| 2021-09-30 | -1229.63% |
| 2021-06-30 | -2127.88% |
| 2021-03-31 | -1003.95% |
| 2020-12-31 | -156.96% |
| 2020-09-30 | -331.11% |
| 2020-06-30 | -451.95% |
| 2020-03-31 | -403.15% |
